Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (2683) 2683
life sciences & biomedicine (2584) 2584
humans (1933) 1933
animals (1455) 1455
glucagon-like peptide-1 receptor (1221) 1221
endocrinology & metabolism (1161) 1161
male (1145) 1145
diabetes mellitus, type 2 - drug therapy (1052) 1052
type 2 diabetes (923) 923
diabetes (903) 903
glucagon (892) 892
glucagon-like peptide-1 (842) 842
hypoglycemic agents - therapeutic use (804) 804
glucagon-like peptide-1 receptor - agonists (768) 768
receptors, glucagon - agonists (669) 669
peptides (644) 644
female (638) 638
insulin (550) 550
mice (549) 549
glucose (537) 537
pharmacology & pharmacy (508) 508
rats (501) 501
peptides - pharmacology (477) 477
receptors, glucagon - metabolism (461) 461
glucagon-like peptide 1 (456) 456
liraglutide (443) 443
diabetes mellitus (439) 439
middle aged (423) 423
hypoglycemic agents - pharmacology (422) 422
glucagon-like peptide-1 receptor - metabolism (405) 405
biological and medical sciences (374) 374
glucagon-like peptide 1 - metabolism (373) 373
venoms - pharmacology (372) 372
exenatide (351) 351
endocrine system (336) 336
analysis (330) 330
digestive, oral, and skin physiology (325) 325
obesity (325) 325
blood glucose - metabolism (312) 312
glucagon-like peptide 1 - analogs & derivatives (309) 309
abridged index medicus (306) 306
glp-1 (299) 299
hypoglycemic agents - adverse effects (296) 296
hypoglycemic agents - administration & dosage (293) 293
insulin - metabolism (291) 291
diabetes mellitus, type 2 - blood (287) 287
peptides - therapeutic use (286) 286
aged (285) 285
treatment outcome (284) 284
hormones, hormone substitutes, and hormone antagonists (282) 282
diabetes mellitus, type 2 - metabolism (281) 281
adult (276) 276
glucagon-like peptide 1 - pharmacology (276) 276
medical sciences (273) 273
internal medicine (270) 270
biochemistry & molecular biology (263) 263
research (263) 263
dextrose (261) 261
blood glucose - drug effects (260) 260
physiological aspects (260) 260
rodents (254) 254
care and treatment (248) 248
hypoglycemic agents (246) 246
risk factors (246) 246
dipeptidyl-peptidase iv inhibitors - therapeutic use (244) 244
mice, inbred c57bl (237) 237
medicine & public health (234) 234
type 2 diabetes mellitus (229) 229
rats, sprague-dawley (224) 224
insulin resistance (223) 223
glucagon-like peptide 1 - therapeutic use (222) 222
insulin secretion (215) 215
incretins - therapeutic use (214) 214
body weight (211) 211
health aspects (211) 211
diabetes therapy (210) 210
venoms - therapeutic use (205) 205
diabetes mellitus, type 2 - complications (200) 200
physiology (191) 191
clinical trials (187) 187
endocrinopathies (186) 186
receptors, glucagon - genetics (186) 186
drug therapy (183) 183
endocrine pancreas. apud cells (179) 179
signal transduction - drug effects (179) 179
general & internal medicine (177) 177
neurosciences (177) 177
diabetes. impaired glucose tolerance (176) 176
signal transduction (175) 175
cardiovascular system & cardiology (173) 173
medicine, research & experimental (172) 172
research & experimental medicine (172) 172
peptides - administration & dosage (170) 170
cell line (169) 169
incretin (169) 169
medicine, general & internal (169) 169
glucagon-like peptide-1 receptor agonist (168) 168
etiopathogenesis. screening. investigations. target tissue resistance (163) 163
neurosciences & neurology (163) 163
exendin-4 (162) 162
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3186) 3186
Spanish (25) 25
Japanese (24) 24
German (17) 17
Chinese (12) 12
French (12) 12
Italian (8) 8
Russian (6) 6
Danish (4) 4
Czech (3) 3
Dutch (1) 1
Hungarian (1) 1
Korean (1) 1
Portuguese (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
by Drucker, Daniel J and Nauck, Michael A
The Lancet (British edition), ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Diabetes. Impaired glucose tolerance | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018
by Dave, Chintan V and Schneeweiss, Sebastian and Wexler, Deborah J and Brill, Gregory and Patorno, Elisabetta
Diabetes care, ISSN 0149-5992, 04/2020, Volume 43, Issue 4, pp. 921 - 924
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | History, 21st Century | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Diabetes Mellitus, Type 2 - epidemiology | Heart Failure - prevention & control | Practice Patterns, Physicians' - statistics & numerical data | Adult | Female | Immunoglobulin Fc Fragments - therapeutic use | Diabetic Angiopathies - prevention & control | Glucagon-Like Peptides - analogs & derivatives | Heart Failure - epidemiology | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Patient Preference - statistics & numerical data | Hypoglycemic Agents - pharmacology | Practice Patterns, Physicians' - trends | Liraglutide - therapeutic use | Diabetic Angiopathies - epidemiology | Aged | Glucagon-Like Peptides - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Type 2 diabetes | Hypoglycemic agents | Research | Diabetes | Drug therapy | Patient outcomes | Myocardial infarction | Cerebral infarction | Receptors | Stroke | Inhibitors | Glucagon | Initiators | Agonists | Research design | Preferences | Heart diseases | Glucagon-like peptide 1 | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
by Rosenstock, Julio and Reusch, Jane and Bush, Mark and Yang, Fred and Stewart, Murray and Albiglutide Study Grp and Albiglutide Study Group and for the Albiglutide Study Group
Diabetes care, ISSN 0149-5992, 10/2009, Volume 32, Issue 10, pp. 1880 - 1886
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Public health. Hygiene-occupational medicine | Public health. Hygiene | Diabetes. Impaired glucose tolerance | Miscellaneous | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Metabolic diseases | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Double-Blind Method | Drug Administration Schedule | Glucagon-Like Peptide 1 - administration & dosage | Glucagon-Like Peptide 1 - analogs & derivatives | Placebo Effect | Humans | Treatment Outcome | Multicenter Studies as Topic | Glucagon-Like Peptide-1 Receptor | Hypoglycemic Agents - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Exercise | Dosage and administration | Metformin | Research | Drug therapy | Health aspects | Studies | Clinical trials | Early intervention | Data analysis | Diabetes | Index Medicus | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
by Secher, Anna and Jelsing, Jacob and Baquero, Arian F and Hecksher-Sørensen, Jacob and Cowley, Michael A and Dalbøge, Louise S and Hansen, Gitte and Grove, Kevin L and Pyke, Charles and Raun, Kirsten and Schäfer, Lauge and Tang-Christensen, Mads and Verma, Saurabh and Witgen, Brent M and Vrang, Niels and Knudsen, Lotte Bjerre
The Journal of clinical investigation, ISSN 0021-9738, 10/2014, Volume 124, Issue 10, pp. 4473 - 4488
Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Vagus Nerve - metabolism | Glucagon-Like Peptide 1 - analogs & derivatives | Glucagon-Like Peptide 1 - pharmacology | Body Weight - drug effects | Electrophysiology | Rats | Receptors, Glucagon - metabolism | Male | Mice, Transgenic | Weight Loss - drug effects | Rats, Sprague-Dawley | Nerve Tissue Proteins - metabolism | Pro-Opiomelanocortin - metabolism | Animals | Hypothalamus - metabolism | Glucagon-Like Peptide-1 Receptor | Arcuate Nucleus of Hypothalamus - drug effects | Paraventricular Hypothalamic Nucleus - metabolism | Mice | Neurons - metabolism | Liraglutide | Disease Models, Animal | Neural circuitry | Medical examination | Patient outcomes | Weight loss | Physiological aspects | Hypothalamus | Observations | Obesity | Weight control | Peptides | Rodents | Software | Physiology | Food | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models
by Hölscher, Christian
Neuropharmacology, ISSN 0028-3908, 07/2018, Volume 136, Issue Pt B, pp. 251 - 259
Inflammation | GLP-1 | Neurodegeneration | Insulin | Growth factors | GIP | Pharmacology & Pharmacy | Neurosciences | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Neuroprotective Agents - therapeutic use | Glucagon-Like Peptide-1 Receptor - metabolism | Animals | Neuroprotective Agents - pharmacology | Humans | Alzheimer Disease - metabolism | Alzheimer Disease - drug therapy | Parkinson Disease - drug therapy | Parkinson Disease - metabolism | Receptors, Gastrointestinal Hormone - metabolism | Receptors, Gastrointestinal Hormone - agonists | Glucagon-Like Peptide-1 Receptor - agonists | Models | Neurons | Alzheimer's disease | Analysis | Risk factors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
by Geloneze, Bruno and de Lima-Júnior, José Carlos and Velloso, Lício A
Drugs (New York, N.Y.), ISSN 0012-6667, 4/2017, Volume 77, Issue 5, pp. 493 - 503
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Brain - drug effects | Brain - metabolism | Glucagon-Like Peptide-1 Receptor - metabolism | Animals | Hypoglycemic Agents - administration & dosage | Adipocytes - metabolism | Humans | Adipocytes - drug effects | Diabetes Mellitus, Type 2 - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Brain | Transcription | Peptides | Glucagon | Circuits | Arcuate nucleus | Parkinsons disease | Homeostasis | Clinical trials | Body weight loss | Hormones | Adipocytes | Hypothalamus | Glucose | Nuclei | Rodents | Hepatology | Nutrients | Physiology | Glucagon-like peptide 1 | Food | Neuropeptide Y | Obesity | Medical research | Diabetes mellitus | Weight loss | Energy expenditure | Metabolism | Insulin | Microglia | Energy balance | Neurotransmitters | Weight control | Gliosis | Amphetamine | Diet | Food intake | Neural networks | Leptin | Genesis | Cocaine- and amphetamine-regulated transcript protein | Cocaine | Diabetes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT‐2 inhibitors and GLP‐1 receptor agonists
by Bonaventura, A and Carbone, S and Dixon, D. L and Abbate, A and Montecucco, F
Journal of internal medicine, ISSN 0954-6820, 07/2019, Volume 286, Issue 1, pp. 16 - 31
anti‐diabetic drugs | heart failure | SGLT‐2 inhibitors | CV disease | GLP‐1 receptor agonists | diabetes | SGLT-2 inhibitors | GLP-1 receptor agonists | anti-diabetic drugs | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Diabetic Cardiomyopathies - prevention & control | Diabetic Angiopathies - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Diabetes Mellitus, Type 2 - complications | Glucagon-Like Peptide-1 Receptor - agonists | Type 2 diabetes | Cardiovascular diseases | Hypoglycemic agents | Glucagon | Complications | Diabetes mellitus | Health risks | Clinical trials | Pharmacology | Glucose | Inhibitors | Sodium | Arteriosclerosis | Atherosclerosis | Agonists | Diabetes | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights